Jaguar Health (JAGX) investor relations material

Executive summary

• Supplement amends the proxy statement for the 2026 annual meeting, reconvened on June 2, 2026, to provide additional details on Proposals 3 and 4 regarding share issuances to C/M Capital.

• Clarifies terms for the Equity Line of Credit (ELOC) and Preferred Stock Purchase Agreement, including specific floor prices and use of proceeds.

Voting matters and shareholder proposals

• Proposal 3 seeks approval for issuing shares to C/M Capital under the ELOC Agreement in excess of 19.99% of outstanding shares, with a floor price of $1.10 per share.

• Proposal 4 seeks approval for issuing shares to C/M Capital under the Preferred Stock Purchase Agreement, including Commencement Shares and shares upon redemption of Series P Preferred Stock, also potentially exceeding 19.99% of outstanding shares.

• Votes previously cast on Proposals 3 and 4 will apply to the amended proposals unless changed by the shareholder.

Shareholder rights and capital structure

• ELOC allows daily sales of up to $1,500,000 in common stock to C/M Capital, subject to price and volume conditions.

• Redemption of Series P Preferred Stock is capped at 19.99% of outstanding shares unless shareholder approval is obtained or the stock is delisted.

• Adjustments to caps and ratios are provided for stock splits, dividends, and similar events.